Naturalistic exploration of the effect of osmotic release oral system‐methylphenidate on remission rate and functional improvement in Taiwanese children with attention‐deficit–hyperactivity disorder

Tzang, Ruu‐Fen; Wang, Ya-Ching; Yeh, Chin‐Bin; Hsu, Cheng-Dien; Liang, Hsin-Yi; Yang, Pinchen; Liu, Hung-Jen; Huang, Yu‐Shu; Cheng, Helen; Hsu, Ya-Chen; Liu, Shen‐Ing; Pan, Chia-Ho; Huang, Yu‐Huei; Huang, Che-Jen; Wu, Yu‐Yu; Huang, Yu-Hsin; Liu, Hui-Ching; Chang, Hsueh‐Ling

doi:10.1111/j.1440-1819.2011.02289.x

Cited by 14 publications

(11 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…29 However, no studies have investigated the relationship between the definition of remission and functional outcomes. A moderate positive correlation was reported between health-related quality of life (measured with ADHD Rating Scale) and symptoms improvement (measured with Child Health and Illness Profile, Child Edition) in children receiving atomoxetine.…”

Section: Discussionmentioning

confidence: 99%

Remission Rate and Functional Outcomes During a 6-Month Treatment With Osmotic-Release Oral-System Methylphenidate in Children With Attention-Deficit/Hyperactivity Disorder

Su¹,

Li²,

Chen³

et al. 2015

Journal of Clinical Psychopharmacology

View full text Add to dashboard Cite

Many definitions have been used to evaluate remission in patients with attention-deficit/hyperactivity disorder (ADHD) in different studies resulting with varied remission rates. This open-label, multicenter study investigated the remission rate in Chinese children (n = 239; aged 6-16 years) with a diagnosis of ADHD (Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition), treated with osmotic-release oral-system methylphenidate at doses of 18, 36, and 54 mg, once daily. Two definitions of remission were used: (1) (primary end point): average scores of SNAP-IV (Swanson, Nolan, and Pelham, Fourth Edition) items of 1 or less (0-3 rating scale for each item) according to the subtype of ADHD (inattentive [1-9], hyperactive-impulsive [10-18], and combined type [1-18]), and (2) total score of SNAP-IV items 1 to 18 of 18 or less, at week 8. The study consisted of screening/baseline, titration/open-label treatment (8 weeks), and extended observation (up to 24 weeks) phases. Secondary efficacy assessments were Clinical Global Impression-Improvement (clinical efficacy), Behavior Rating Inventory of Executive Function Scale (BRIEF; executive function behaviors), and Weiss Functional Impairment Rating Scale (social function). Validity of remission was assessed by comparing the function measures (BRIEF and Weiss's) between patients who achieved remission and those who did not. At week 8, 69.3% (151/218) of patients achieved remission by definition 1, and 73.2% (161/220) by definition 2. At weeks 8 and 24, the remission group had significantly lower BRIEF, Weiss's, and Clinical Global Impression-Improvement scores (P < 0.001 for all) compared with the nonremission group. Overall, treatment with osmotic-release oral-system methylphenidate was well tolerated, with increased remission rates in children with ADHD.

show abstract

Section: Discussionmentioning

confidence: 99%

Remission Rate and Functional Outcomes During a 6-Month Treatment With Osmotic-Release Oral-System Methylphenidate in Children With Attention-Deficit/Hyperactivity Disorder

Su¹,

Li²,

Chen³

et al. 2015

Journal of Clinical Psychopharmacology

View full text Add to dashboard Cite

show abstract

“…[ 9 26 ] A study in Chinese population in Taiwan of China showed 44.2% of symptomatic remission at week 4, 58.8% at week 6, and 59.6% at week 10 (average dose: 36.7 mg/d). [ 26 ] In another study,[ 28 ] the remission rate (Swanson, Nolan and Pelham, version IV scale, Chinese version [SNAP-IV-C]) was 30.7% after 48-weeks treatment with 30.16 mg/d dose. In comparison, lower average dose (22.8 mg/d) was observed in the current study that resulted in a higher and faster remission.…”

Section: Discussionmentioning

confidence: 99%

“…Further, a high compliance rate (93.6%) and enrollment of patients with mild ADHD and the difference in remission definition and evaluation tools may have contributed to the difference in the remission rates in the current study. We defined remission rate as the rate of children with average total score ≤5 based on IOWA Conners I/O subscale, whereas the other studies[ 9 26 28 ] used SNAP-IV-C scale where <1 (“not at all” or “just a little” in ADHD symptom) score on each of the 18 ADHD items was considered remission rate.…”

Section: Discussionmentioning

confidence: 99%

An Open-label, Self-control, Prospective Study on Cognitive Function, Academic Performance, and Tolerability of Osmotic-release Oral System Methylphenidate in Children with Attention-deficit Hyperactivity Disorder

Zheng

Liang

Gao

et al. 2015

Chinese Medical Journal

View full text Add to dashboard Cite

Background:Attention-deficit hyperactivity disorder (ADHD) is the most common mental and behavioral disorder in school-aged children. This study evaluated the effect of osmotic-release oral system (OROS) methylphenidate (MPH) on cognitive function and academic performance of Chinese school-aged children with ADHD.Methods:This 12-week, prospective, multicenter, open-label, self-controlled study enrolled 153 Chinese school-aged children with ADHD and 41 non-ADHD children. Children with ADHD were treated with once-daily OROS-MPH (18 mg, 36 mg, or 54 mg). The primary endpoints were Inattention/Overactivity (I/O) with Aggression Conners Behavior Rating Scale (IOWA) and Digit Span Test at week 12 compared with baseline. Secondary endpoints included opposition/defiant (O/D) subscale of IOWA, Clinical Global Impression (CGI), Coding Test, Stroop Color-word Test, Wisconsin Card Sorting Test (WCST), academic performance on teacher-rated school examinations, and safety at week 12 compared with baseline. Both non-ADHD and ADHD children received the same frequency of cognitive operational test to avoid the possible bias caused by training.Results:A total of 128 patients were evaluated with cognitive assessments. The OROS-MPH treatment significantly improved IOWA Conners I/O subscale scores at week 12 (3.8 ± 2.3) versus baseline (10.0 ± 2.4; P < 0.0001). Digit Span Test scores improved significantly (P < 0.0001) with a high remission rate (81.1%) at week 12 versus baseline. A significant (P < 0.0001) improvement was observed in O/D subscale of IOWA, CGI, Coding Test, Stroop Color-word Test, WCST, and academic performance at week 12 versus baseline. Very few practice-related improvements were noticed in the non-ADHD group at week 12 compared with baseline. No serious adverse events and deaths were reported during the study.Conclusions:The OROS-MPH treatment effectively controlled symptoms of ADHD and significantly improved academic performance and cognitive function of Chinese school-aged children with ADHD. The treatment was found to be safe and generally well-tolerated over 12 weeks.Trial Registration:ClinicalTrials.gov, NCT01933880; http://clinicaltrials.gov/ct2/show/NCT01933880?term=CONCERTAATT4099&rank=1

show abstract

“…The findings of the current study are generally consistent with prior reports. However, previous research that used DSM-oriented ADHD-symptom rating scales for outcome measurements have demonstrated significant improvements in the parent-rated behavioural symptoms 21,30. Changes in the DSM-oriented ADHD-symptoms were reported not to be significantly different among ADHD subtypes after treatment 31.…”

Section: Discussionmentioning

confidence: 80%

Changes in Behaviour Symptoms of Patients with Attention Deficit/Hyperactivity Disorder during Treatment: Observation from Different Informants

Wang

Chen

Huang

2013

Psychiatry Investig

Self Cite

View full text Add to dashboard Cite

ObjectiveThe aim of this study was to determine changes in behaviour among patients with attention deficit/hyperactivity disorder (ADHD) by different informants during treatment in the clinical setting.MethodsSeventy-nine patients with ADHD were recruited. They completed 12-months of treatment with oral short-acting methylphenidate, two-to-three times per day, at a dose of 0.3-1.0 mg/kg. Among the 79 patients (mean age, 9.1±1.9 years), 39 were classified as the ADHD-C/H type (hyperactive-impulsive type and combined type) and 40 as the ADHD-I type (inattentive type). At baseline, and after 12 months, their behaviour was assessed using the Child Behaviour Checklist (CBCL), Teacher's Report Form (TRF), ADHD Rating Scale (ADHD-RS), and Clinical Global Impression-Severity (CGI-S).ResultsPatients classified as the ADHD-C/H type had higher scores on three CBCL subscales, on the ADHD-RS and CGI-S compared to the ADHD-I type patients. After 12-months of treatment, for all patients, there were significant improvements in the four subscales of the TRF as well as the ADHD-RS and CGI-S scores, but not on the CBCL. In addition, the patients with the ADHD-C/H type had greater improvements on the four subscales of the TRF after treatment. However, there were no differences noted on the CBCL, ADHD-RS and CGI-S.ConclusionThe results of this study showed that during treatment, in the clinical setting, there are different assessments of behaviour symptoms, associated with ADHD, reported by different informants. Assessments of behaviour profiles from multiple informants are crucial for establishing a fuller picture of patients with ADHD.

show abstract

Naturalistic exploration of the effect of osmotic release oral system‐methylphenidate on remission rate and functional improvement in Taiwanese children with attention‐deficit–hyperactivity disorder

Cited by 14 publications

References 26 publications

Remission Rate and Functional Outcomes During a 6-Month Treatment With Osmotic-Release Oral-System Methylphenidate in Children With Attention-Deficit/Hyperactivity Disorder

Remission Rate and Functional Outcomes During a 6-Month Treatment With Osmotic-Release Oral-System Methylphenidate in Children With Attention-Deficit/Hyperactivity Disorder

An Open-label, Self-control, Prospective Study on Cognitive Function, Academic Performance, and Tolerability of Osmotic-release Oral System Methylphenidate in Children with Attention-deficit Hyperactivity Disorder

Changes in Behaviour Symptoms of Patients with Attention Deficit/Hyperactivity Disorder during Treatment: Observation from Different Informants

Contact Info

Product

Resources

About